HOME >> BIOLOGY >> NEWS
Acorda Therapeutics receives L.W. Freeman Award for Scientific Research

Hawthorne, NY /Mesa, AZ November 13, 2002 - Acorda Therapeutics, a biotechnology company located in Hawthorne, NY, will receive the L.W. Freeman Award for Scientific Research tomorrow evening at the National Spinal Cord Injury Association (NSCIA) 2002 Annual Conference in Mesa, AZ.

This award is given annually for pioneering research on regeneration in spinal cord injury or disease and was established in memory of Dr. L. W. Freeman, who was one of the original members of the NSCIA Medical Advisory Committee. A scientist at Indiana University, Dr. Freeman was committed to research that advanced the knowledge of treatment for spinal cord injury. Dr. Freeman was a tireless researcher and teacher, and he served as a key advisor to the Association until his death in 1969.

Marcie Roth, Executive Director of the NSCIA, said, "The NSCIA recognizes the significant contribution that Acorda Therapeutics is making in scientific research that benefits the spinal cord injury community. Acorda's research platform encompasses a broad range of therapeutic targets ranging from regenerative therapies to therapies focused on improved function designed to improve the quality of life and overall health for persons living with a spinal cord injury."

Ron Cohen, M.D., Founder and CEO of Acorda Therapeutics, said, "Acorda is the first company to focus on the development of therapies to restore function in people with SCI. We are proud to be working with the NSCIA to achieve this and are honored to accept this award. Our lead product, Fampridine-SR, entered Phase 3 clinical trials for chronic SCI this year. This is the first time a therapy for improving function in chronic SCI has reached that milestone. Our relationship with the NSCIA continues to be an important catalyst in helping to move the research and education forward in SCI."

The awards ceremony will take place at The Sheraton Mesa Hotel and Convention Center at 6:00 pm on Thursday, November 14, 20
'"/>

Contact: Tierney Saccavino, Acorda
tsaccavino@acorda.com
914-347-4300
Porter Novelli
13-Nov-2002


Page: 1 2

Related biology news :

1. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
2. Acorda Therapeutics acquires CeNeS neuregulin products
3. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
4. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
5. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
7. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
8. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
9. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
10. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
11. Immerge BioTherapeutics announces identification of PERV receptor

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... (PRWEB) , ... November 13, 2019 , ... Personalized ... the first patients in an FDA approved clinical trial for stem cell treatment ... the formation of the company as a subsidiary of VetStem Biopharma. , In July ...
(Date:11/12/2019)... ... 12, 2019 , ... The Arnold and Mabel Beckman Foundation ... institutions for its Instrumentation Grant for Advanced Light-Sheet Microscopy and Data Science ... for the acquisition of instrumentation, development and maintenance; support for data science collaborations ...
(Date:11/9/2019)... ... November 08, 2019 , ... StageBio ... histology, pathology, biomarker development, and archiving services for the biopharmaceutical, medical device ... Histo-Scientific Research Laboratories (HSRL), Vet Path Services (VPS) and Tox Path Specialists ...
Breaking Biology News(10 mins):
(Date:11/5/2019)... , ... November 04, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... cell line development technology, GPEx® Boost. The technology enhances Catalent’s proven GPEx ...
(Date:11/2/2019)... , ... October 31, 2019 , ... ... Adaptive Biotechnologies in a live webinar on Friday, November 15, ... immuno-oncology. , Immunosequencing, the science of profiling T-cell receptors (TCRs) and B-cell ...
(Date:10/29/2019)... ... 28, 2019 , ... CaroGen Corporation , a biotechnology company, today announced ... Professor Jack R Wands, MD, of Brown University , Dr. Steve Projan, ... Mor, MD, PhD, of Wayne State University, formerly a professor at Yale University School ...
(Date:10/22/2019)... ... ... nQ Medical, Inc. of Cambridge, MA, was recognized in the top 5 ... at a showcase event yesterday in Los Angeles. nQ competed against 3,500 early-stage U.S. ... near-term growth projections to be named one of the most fundable companies in America. ...
Breaking Biology Technology:
Cached News: